Wall Street Zen Upgrades Silence Therapeutics (NASDAQ:SLN) to “Hold”

Silence Therapeutics (NASDAQ:SLNGet Free Report) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

A number of other equities research analysts also recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a research report on Friday. BMO Capital Markets decreased their price target on Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 4th. The Goldman Sachs Group lowered their price target on Silence Therapeutics from $4.00 to $3.00 and set a “sell” rating for the company in a report on Friday, May 9th. Morgan Stanley cut their price objective on shares of Silence Therapeutics from $45.00 to $25.00 and set an “overweight” rating on the stock in a report on Friday, May 9th. Finally, Chardan Capital reissued a “buy” rating and issued a $35.00 target price on shares of Silence Therapeutics in a research report on Friday. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Silence Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.83.

Get Our Latest Research Report on Silence Therapeutics

Silence Therapeutics Price Performance

NASDAQ:SLN opened at $5.33 on Friday. The firm has a market cap of $159.53 million, a PE ratio of -3.39 and a beta of 1.41. The firm has a 50 day simple moving average of $4.13 and a 200-day simple moving average of $4.92. Silence Therapeutics has a 1-year low of $1.97 and a 1-year high of $22.47.

Silence Therapeutics (NASDAQ:SLNGet Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.42). The firm had revenue of $0.14 million during the quarter, compared to analysts’ expectations of $3.58 million. Silence Therapeutics had a negative return on equity of 62.81% and a negative net margin of 342.00%. As a group, sell-side analysts expect that Silence Therapeutics will post -1.77 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Silence Therapeutics

A number of institutional investors have recently added to or reduced their stakes in SLN. Nantahala Capital Management LLC raised its holdings in shares of Silence Therapeutics by 424.8% in the 4th quarter. Nantahala Capital Management LLC now owns 1,049,676 shares of the company’s stock worth $7,222,000 after purchasing an additional 849,676 shares during the period. Redmile Group LLC grew its holdings in shares of Silence Therapeutics by 26.3% during the 4th quarter. Redmile Group LLC now owns 2,399,317 shares of the company’s stock worth $16,507,000 after purchasing an additional 500,000 shares during the period. Bank of America Corp DE increased its position in Silence Therapeutics by 48,165.6% during the 4th quarter. Bank of America Corp DE now owns 499,066 shares of the company’s stock worth $3,434,000 after purchasing an additional 498,032 shares in the last quarter. Marshall Wace LLP raised its holdings in Silence Therapeutics by 190.3% in the fourth quarter. Marshall Wace LLP now owns 488,889 shares of the company’s stock valued at $3,364,000 after buying an additional 320,472 shares during the period. Finally, Cantor Fitzgerald L. P. raised its holdings in Silence Therapeutics by 61.5% in the fourth quarter. Cantor Fitzgerald L. P. now owns 539,726 shares of the company’s stock valued at $3,713,000 after buying an additional 205,534 shares during the period. Hedge funds and other institutional investors own 98.73% of the company’s stock.

About Silence Therapeutics

(Get Free Report)

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.

See Also

Analyst Recommendations for Silence Therapeutics (NASDAQ:SLN)

Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.